Abstract 1430P
Background
In patients with advanced non-small cell lung cancer (aNSCLC) timely therapeutic decision making is critical. In the past decade the treatment options for aNSCLC have expanded, along increased numbers of biomarkers that need to be tested, often on small and sparse material with multiple testing technologies. This may result in an undesired prolonged time to treatment and in the worst case even to non-feasible analysis. To elucidate the performance of the Idylla™ GeneFusion Assay, which simultaneously covers the biomarkers ALK, ROS1, RET and MET exon 14 skipping, a multicenter study was conducted in a routine clinical setting involving 12 clinical centers across Europe.
Methods
A total of 326 archival aNSCLC formalin fixed paraffin embedded (FFPE) samples were included. The results of the Idylla™ GeneFusion Assay were compared with the biomarker status determined earlier with routine reference methods (including FISH, IHC, RT-PCR, and NGS). A total of 179 biomarker positive cases (85 ALK, 33 ROS1, 20 RET and 41 MET exon 14 skipping) were included, making this one of the largest fusion positive datasets tested. The Idylla™ detects ALK, ROS1 and RET fusions using both fusion specific and expression imbalance detection, allowing for the detection of less common fusions not covered by the fusion specific PCR’s.
Results
FFPE sample types used were 44% resected specimen, 46% tissue biopsies, 9% cytological specimen and 1% unknown. 67% of the centers used only 1 or 2 FFPE sections (5 or 10μm). The Idylla™ GeneFusion Assay demonstrated a low failure rate (0.9%). It showed also a high sensitivity/specificity, respectively for the following actionable biomarkers in NSCLC: 96.1%/99.6% for ALK, 96.5%/98.9% for ROS1, 100%/99.6% for RET and 92.5%/100% for MET exon 14 skipping.
Conclusions
Since results are available within 3 hours, the Idylla™ GeneFusion Assay technology has emerged as a highly relevant time efficient upfront screening tool in FFPE samples. Moreover, detection of potentially novel fusions based on the principle of expression imbalance may be easily verified with either IHC, FISH or NGS without delaying the treatment initiation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Biocartis NV.
Funding
Biocartis.
Disclosure
A. Hartmann, A. Hirschmann, P. Hofman, A. Concha, S. Mrabet-Dahbi, P. Vannuffel, E. Watkin, M. Putzova, S. Scarpino, A. Cayre, P. Martin, L.C. Melchior: Other, Institutional, Part of this industry sponsored study (Biocartis NV): Biocartis.
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20